BioSpace News Archive

AbCellera Raises $105 Million Series B to Expand Therapeutic Antibody Manufacturing

As part of the scale-up, it plans to hire up to 100 new staffers, bringing total headcount to about 240.

May 27, 2020
·
4 min read
·
Mark Terry
FDA

BMS’ Opdivo and Yervoy Combination Treatment Snags Two Approvals in Lung Cancer this Month

Bristol Myers Squibb is doing its best to claim market share in the checkpoint inhibitor space and over the past month, the company is pushing its way forward with a pair of regulatory approvals in lung cancer.

May 27, 2020
·
2 min read
·
Alex Keown
Policy

Biopharma Update on the Novel Coronavirus: May 27

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.

May 27, 2020
·
4 min read
·
BioSpace Editorial Staff
Business

Q32 Bio Launches with $46 Million and IL-7 Inhibitor Licensed from BMS

With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.

May 27, 2020
·
3 min read
·
Alex Keown
Business

What Masks Can and Can’t Do, and Why You Should Wear One

Michael Bell, M.D., deputy director of the Division of Healthcare Quality Promotion at the Centers for Disease Control, teamed up with the Pandemic Action Network to help answer such questions and combat misinformation.

May 27, 2020
·
4 min read
·
Gail Dutton
Business

BMS Drops $65 Million on Multi-Target Discovery Deal with Repare Therapeutics

This morning, the two companies announced a global collaboration that will harness the power of Repare’s CRISPR-enabled platform to discover the next generation of precision oncology medicines.

May 27, 2020
·
2 min read
·
Alex Keown
Business

Gilead Doubles Down on Immuno-Oncology with 10-Year Pact with Arcus Biosciences

Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.

May 27, 2020
·
4 min read
·
Mark Terry
Drug Development

Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration.

May 27, 2020
·
3 min read
·
Krystle Vermes
Business

Genentech Launches COVID-19 Study Focused on Underserved Minority Populations

Since COVID-19 began its sweep across the United States, data has shown the disease caused by the novel coronavirus has disproportionately impacted racial and ethnic minority groups across the country.

May 27, 2020
·
3 min read
·
Alex Keown
BioSpace Global Roundup, May 28

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

May 27, 2020
·
4 min read
·
Alex Keown